Tandem Diabetes (TNDM) announced that the U.S. Food and Drug Administration has cleared the Android version of the Tandem Mobi mobile app. The app enables users to manage their diabetes directly from their personal, compatible Android smartphone. A limited release is expected to start in December 2025, followed by commercial availability in early 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care Q3 2025 Earnings: Record Sales & Growth
- Tandem Diabetes price target raised to $16 from $15 at Stifel
- Tandem Diabetes price target raised to $16 from $14 at Goldman Sachs
- Tandem Diabetes price target raised to $18 from $16 at Mizuho
- Tandem Diabetes Care: Strong Buy Rating Backed by Strategic Growth Initiatives and Attractive Valuation